Microvascular brain pathology and late-life motor impairment
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received June 24, 2012
- Accepted September 28, 2012
- First Published January 30, 2013.
Article Versions
- Previous version (January 30, 2013 - 13:03).
- You are viewing the most recent version of this article.
Author Disclosures
- Aron S. Buchman, MD,
- Lei Yu, PhD,
- Patricia A. Boyle, PhD,
- Steven R. Levine, MD,
- Sukriti Nag, MD, PhD,
- Julie A. Schneider, MD and
- David A. Bennett, MD
- Aron S. Buchman, MD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
(1) NIH R01AG17917, co-I, 2001-13; (2) NIH R01AG24480, PI, 2005-12, R01AG043379 (PI), 2012-2017, R01NS078009 (PI), 2012-2017
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Lei Yu, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH R01AG033678 [co-investigator], NIH R01AG024871 [co-investigator], NIH R01AG024871 [co-investigator], NIH P30AG010161 [co-investigator], NIH R01AG015819 [co-investigator], NIH R01HL096944 [co-investigator], NIH R01AG036042 [co-investigator], NIH R01AG038651 [co-investigator], NIH R01AG040039 [co-investigator], NIH R01AG034374 [co-investigator], NIH U01AG032984 [co-investigator]
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Patricia A. Boyle, PhD,
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NIH/NIA R01AG034374, PI, 2009-2014NIH/NIA R01AF034119, Co-I, NIH/NIA R01AG033678, PI, 2009-2014
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Steven R. Levine, MD,
(1) Independent Medical/Safety Monitor for NINDS-funded IMS 3, FAST MAG, INSTINCT, and CLEAR-ER(2) Adjudication committee for NINDS-funded WARCEF
NONE
(1) Genentech-sponsored investigator meeting - travel expenses reimbursement in 2010, 2011
(1) MEDLINK, Associate Editor, 1996-present(2) National Stroke Association, scientific content advisor, 2010, 2011
NONE
(1) Book: Transient Ischemic Attacks, Blackwell Futura, 2004
NONE
(1) Genentech-sponsored investigator meeting - consultant, 2010(2) Genentech study on cost-effectiveness of primary stroke centers, 2011 - consultant within a study group
(1)Medical Education Speakers Network, lecturer, 2008-2012(2)NCME, lecturer, 2008-2011
NONE
NONE
NONE
(1)NIH-NHLBI 1R01 HL096944, principal investigator, 2009-2013(2) NIH-NINDS 1UO1 NS044364, Independent safety monitor, 2003 - 2012(3) NIH-NINDS 1 U10 NS077378,PI, 2011 - 2017(4) NIH-NINDS 1 U10 NS080377, PI, 2012 - 2017(5) NIH-NINDS 1 R25 NS079211, MPI, 2012- 2017(6) The Patient-Centered Outcomes Research Institute (PCORI) 1IP2PI000781, scientific PI, 2012-2014(7) NIH-NIA 1 R01 AG040039, Co-I, 2011-2016(8) NIH-NINDS 2 P50 NS044283, safety monitor, 2008-2013(9) NIH-NINDS 2 U01 NS052220, independent medical monitor, 2005-2013
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Sukriti Nag, MD, PhD,
NONE
NONE
NONE
NONE
NONE
The blood-brain & Other neural barriers, Springer Science+ Business Media,Humana Press, 2011Nag S (Editor)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- Julie A. Schneider, MD and
1. served on scientific advisory board for GE Healthcare(2010)2. served on scientific advisory board for Eli Lilly andCompany (2011)
NONE
NONE
2005-current Journal Histochemistry and Cytochemistry (Monitoring editor)2008-current International Journal of Clinical andExperimental Pathology (IJCEP, ISSN 1936-2625) (Editorial Board)2010 Journal of Alzheimer's Disease (Associate Editor)
NONE
NONE
NONE
Neuropathology consultant, AVID radiopharmaceuticals 2009-12
NONE
NONE
NONE
AVID radiopharmaceutical phase III clinical trialNeuropathologist 2010-2011
1R01AG042210 (Schneider)07/1/12- 06/30/17Epidemiologic Study of TDP-43 Pathology in Aging andDementia Major goal is to determine whether age-related TDP-43pathology represents a separate pathologic processassociated with a dementia syndrome with a distinctcognitive phenotype and specific genetic risk factors thatare separate from AD.Role: Principal investigator
R01NS078009 (Buchman) 9/15/12-6/30/17 NINDS The Clinical Profile of Parkinson's Disease (PD)Pathology. The overall goal is to characterize the clinical profileof PD pathology in older persons without a diagnosis of PD.Role: co-investigator
R01AG043379 (Buchman) 9/30/12-8/31/17 NIA Brain and Spinal Cord Microvascular Pathology in Late-LifeMotor ImpairmentThe overall goal is to test the hypothesis that specificmicrovascular pathologies in the brain and spinal cordcontribute to late-life motor impairment.
U01AG016976 (Kukull/Montine) 7/1/12-6/30/13 NIA (Pilot) Optimization of Neuropathologic Assessment ofAlzheimer's Disease; The overall goal is to optimizeneuropathologic diagnosis of Alzheimer's disease foruniformity and accurancy across centersRole: Site Principal Investigator
P30 AG10161 (Bennett)9/30/91-6/30/16Rush Alzheimer's Disease Core CenterMajor goals to provide core infrastructure support forresearch regarding aging/dementia/AD. Role: Associate Director, Core Leader: Neuropathology Core
R01 AG031553 (Morris)3/15/08 - 2/28/13Epidemiologic Study of Brain Vitamin E, Diet, andAge-Related Neurologic Diseases; Major goal is analyzeVitamin E in brain, CSF, serum, and diet and compare toneuropathology and dementia. Role: Co-Principal Investigator
R01 AG17917 (Bennett)9/30/01-6/30/13Epidemiologic Study of Neural Reserve and Neurobiology ofAging; Major goals are to identify structural bases of reserveand examine mechanisms risk factors lead to age-relatedfunctional impairment.Role: Co-Investigator
R01 AG15819 (7/1/98 - 6/30/13Risk Factors, Pathology and Clinical Expressions of ADThe major goals of this project are to examine thepathologic mechanisms through which risk factors lead toclinical AD. Role: Co-investigator
P01 AG14449 (Mufson)9/1/97 - 3/31/13 Neurobiology of Mild cognitive impairment in the Elderly;The major goals are to identify neurobiologic substratesof mild cognitive impairment. Role: Co-investigator (Neuropathologist)
R01AG033678-01 (Boyle)9/15/2009 - 6/30/14Epidemiologic study of impaired decision making inpreclinical Alzheimer's disease.The overall goal of the proposed epidemiologic study is toexamine the causes and consequences of impaireddecision-making in old age.Role: Neuropathologist
R01AG034374 (Boyle)8/15/2009 -7/31/14Characterizing the behavior profile of healthy cognitiveaging.Goal is to use innovative statistical approaches tocharacterize the profile of healthy cognitive agingdefined as age-related cognitive change not accounted forby the presence of common neuropathologies (i.e.,Alzheimer's disease, cerebral infarcts, and the Lewy bodydiseases) or terminal decline.Role: Neuropathologist.
P01 AG09466 (deToledo-Morrell) 4/1/1991-8/31/12 Anatomic, Physiologic, Cognitive Pathology of AD; majorgoals- to identify neurobiologic, radiologic, physiologic,cognitive markers with AD; Role: Co-Investigator; Neuropathologist, Administrative Core
R01 AG36042 (Bennett)9/15/09-8/31/14Exploring the Role of the Brain Epigenome: CognitiveDecline and Life ExperiencesThe goal of the study is to examine the relation of DNAmethylation to cognitive decline and life experiences.Role: Neuropathologist
R01 HL096944 (Levine)9/1/09 - 6/30/13Stroke and aPL: Community-Based Clinicopathologic StudyThe major goal of this project is to investigate the roleand mechanisms of antiphospholipid antibodies (aPL) in thedevelopment of pathologically-proven ischemic braininfarction.Role: Neuropathologist
R01AG040039 (Arvanitakis)9/30/11-8/31/16 NationalInstitute on AgingVascular Cognitive and Motor Decline: Impact of aPLThe major goal of this project is to investigate the roleand mechanisms of antiphospholipid antibodies (aPL) in thedevelopment of cognitive and motor decline in aging.
R01AG039478 (Arnold)4/1/11-3/31/16 NationalInstitute on AgingTargeted Proteomics of Resilient Cognition in AgingThe major goal of the study is to identify candidateproteins and pathways that best confer cognitiveresilience despite the accumulation of neurodegenerativedisease pathology.Role: Neuropathologist
R01AG036836 (DeJager)9/15/11-8/31/15 National Institute on AgingExploring the Role of the Brain Transcriptome in CognitiveDeclineThe major goal is to investigate the transcriptome ofhuman brain tissue to identify molecular pathways thatcontribute to cognitive decline. Role: Neuropathologist
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- David A. Bennett, MD
(1) Vigorous Minds, Scientific Advisory Board
NONE
Danone, paid for travel to scientific meeting
(1) Neurology, Editorial Board;(2) Current Alzheimer Research, Editorial Board;(3) Neuroepidemiology, Editorial Board(4) Frontiers Neurology, Editorial Board
NONE
NONE
NONE
(1) Danone, Inc., (2) Wilmar Schwabe GmbH & Co., (3) Eli Lilly, Inc., (4) the Gerson Lehrman Group
NONE
NONE
NONE
(1) Danone Inc., PI
NIH: P30AG10161, PI; R01AG15819, PI; R01AG17917, PI; R01AG36042, PI; U01AG32984, Co-I; R01AG22018, Co-I; R01AG33678, Co-I; R01AG36836, Co-I; R01AG41797, Co-I; R01AG42210, Co-I; and Illinois Department Public Health
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
- From the Rush Alzheimer's Disease Center (A.S.B., L.Y., P.A.B., S.N., J.A.S., D.A.B.), Neurological Sciences (A.S.B., L.Y., D.A.B.), Behavioral Science (P.A.B.), and Pathology (S.N., J.A.S.), Rush University Medical Center, Chicago, IL; and Departments of Neurology (Stroke Center) and Emergency Medicine (S.R.L.), SUNY Downstate Medical Center, Brooklyn, NY.
- Correspondence to Dr. Buchman: Aron_S_Buchman{at}rush.edu
Article usage
Cited By...
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.